Madrigal Pharmaceuticals (MDGL) Expected to Post Quarterly Earnings on Tuesday

Madrigal Pharmaceuticals (NASDAQ:MDGL) is projected to post its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.8629) per share and revenue of $404.17 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.99) EPS for the quarter, beating analysts’ consensus estimates of ($2.68) by $0.69. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. The business had revenue of $364.25 million for the quarter, compared to analysts’ expectations of $352.13 million. During the same period last year, the business earned ($1.90) earnings per share. The business’s quarterly revenue was up 71.2% on a year-over-year basis. On average, analysts expect Madrigal Pharmaceuticals to post ($7.03) EPS for the current fiscal year and $5.30 EPS for the next fiscal year.

Madrigal Pharmaceuticals Stock Up 0.8%

Shares of NASDAQ MDGL opened at $437.74 on Tuesday. The stock has a market capitalization of $10.11 billion, a P/E ratio of -33.96 and a beta of -1.04. Madrigal Pharmaceuticals has a one year low of $393.61 and a one year high of $615.00. The firm’s 50 day simple moving average is $506.16 and its two-hundred day simple moving average is $501.82. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.20 and a quick ratio of 2.94.

Insiders Place Their Bets

In other Madrigal Pharmaceuticals news, CEO William Sibold sold 5,221 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $542.39, for a total value of $2,831,818.19. Following the sale, the chief executive officer owned 197,746 shares of the company’s stock, valued at $107,255,452.94. This trade represents a 2.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Shannon Kelley sold 664 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $514.97, for a total transaction of $341,940.08. Following the completion of the transaction, the general counsel owned 11,474 shares in the company, valued at $5,908,765.78. The trade was a 5.47% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 12,247 shares of company stock worth $6,581,182. Insiders own 17.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. UBS Group restated a “buy” rating and issued a $735.00 price objective on shares of Madrigal Pharmaceuticals in a report on Wednesday, October 14th. Wolfe Research raised shares of Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 target price on the stock in a report on Tuesday, August 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, October 15th. Barclays lowered their price target on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating for the company in a research note on Monday, August 3rd. Finally, Canaccord Genuity Group boosted their price target on shares of Madrigal Pharmaceuticals from $578.00 to $587.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Fifteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $699.20.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.